Pharma BD Deal Intelligence
Teva's $2.3B bet on Rimsa to expand its Latin America presence turned into a bust—the Mexico-based drugmaker's finances proved to be a house of cards, forcing Teva to walk away from the deal within months and write off the investment entirely.
Teva acquired Rimsa for ~$2.3B, a Mexico-based pharmaceutical company.
Derivative suit sheds light on Teva disastrous Rimsa acquisition revealing fraud discovered one week after closing with over $1 billion in write-offs.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Teva acquired Rimsa for ~$2.3B, a Mexico-based pharmaceutical company.
Teva/Rimsa is a geographic platform (Mexico/Latin America generics distribution). Competitive landscape is at the distribution-channel level (Genomma Lab, Sanfer, Landsteiner) rather than per-asset.
Teva completed ~$2.3B acquisition of Rimsa, Mexico's largest pharma company, expanding Latin American generics and specialty presence.
Teva disclosed accounting irregularities at Rimsa post-close, leading to financial restatements and legal disputes with former shareholders.
Rimsa plagued by post-close accounting irregularities and legal disputes. Combined with Teva's broader financial challenges, deal added risk not growth.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Rimsa (this deal) | 2015 | $2.3B | 8 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2015 deals · Teva Pharmaceutical Industries Ltd. deals